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Abstract. At the end phase of the Global Programme to Eliminate Lymphatic Filariasis, antibody testing may have a
role in decision-making for bancroftian ﬁlariasis–endemic areas. This study evaluated the diagnostic performance of BLF
Rapid™, a prototype immunochromatographic IgG4-based test using BmSXP recombinant protein, for detection of
bancroftian ﬁlariasis. The test was evaluated using 258 serum samples, comprising 96 samples tested at Universiti Sains
Malaysia (in-house) and 162 samples tested independently at three international laboratories in the USA and India, and
two laboratories in Malaysia. The independent testing involved 99 samples from Wuchereria bancrofti microﬁlaria or
antigen positive individuals and 63 samples from people who were healthy or had other infections. The in-house eval-
uation showed 100%diagnostic sensitivity and speciﬁcity. The independent evaluations showed a diagnostic sensitivity
of 84–100% and 100% speciﬁcity (excluding non-lymphatic ﬁlarial infections). BLF Rapid has potential as a surveillance
diagnostic tool to make “Transmission Assessment Survey”–stopping decisions and conduct post-elimination
surveillance.
Lymphatic ﬁlariasis (LF), caused by the ﬁlariae worms
Wuchereria bancrofti, Brugia malayi, and Brugia timori, is a
neglected tropical diseaseendemic in 53countries.1 Infection,
typically acquired in childhood, is often asymptomatic with
clinical manifestations that may present later in life.2 Although
it is rarely fatal, LF is a major cause of suffering and disability,
and has substantial social and economic impact. In theGlobal
Burden of Disease study in 2016, LF accounted for 1.189
million disability-adjusted life years.3
The Global Programme to Eliminate Lymphatic Filariasis
(GPELF) was established by the World Health Organization to
eliminate LF as a public health problem by the year 2020.
Preventive chemotherapy bymass drug administration (MDA)
is the core strategy of the program, followed by morbidity
management and disability prevention.4 As of 2016, an esti-
mated 495.6 million people in 40 countries have received
MDA.1
The GPELF requires diagnostic tools for mapping LF dis-
tribution, monitoring of MDA progress, makingMDA stopping
decisions, and conducting post-MDA surveillance, including
transmission assessment surveys (TAS). The current test used
for TAS in bancroftian ﬁlariasis–endemic areas is the Filariasis
Test Strip (Abbott, Scarborough, ME), which is a modiﬁed
version of the previous Alere BinaxNOW® Filariasis (Alere,
Scarborough, ME) card test (immunochromatographic test
[ICT]). It detects circulatingW. bancrofti antigen in blood and
has been useful in various activities of the GPELF.4 However,
as LF prevalence declines, an antibody detection test may be
needed to conﬁrm interruption of transmission because
ﬁlarial-speciﬁc antibodies provide an early indicator of expo-
sure to ﬁlarial parasites.5 Inbrugian ﬁlariasis endemicareas, an
IgG4 antibody test based on BmR1 recombinant protein
(Brugia Rapid; Reszon Diagnostics International Sdn. Bhd.,
Selangor, Malaysia), has been useful for TAS activities.6
At Universiti Sains Malaysia (USM), we have developed a
prototype antibody detection rapid test for bancroftian ﬁlari-
asis calledBLFRapid. It is based on immunochromatographic
technology and detects the presence of speciﬁc anti-ﬁlarial
IgG4 against BmSXP recombinant protein in serum samples
of bancroftian ﬁlariasis patients. In this study, the main aim
was to assess the diagnostic performance of BLF Rapid by
evaluating its diagnostic sensitivity and speciﬁcity. It was
tested at USM and ﬁve other laboratories using stored sam-
ples in the serumbank of the respective laboratories. This was
an initial step in assessing the potential of BLF Rapid to assist
in the LF elimination program in bancroftian ﬁlariasis endemic
areas.
As shown in Figure 1A, BLF Rapid comprises BmSXP
recombinant protein as the test line (position C) and anti-
mouse IgG as the reagent control line (position B). Another
commercial testwhich containsBmSXP is calledPanLFRapid
(Reszon Diagnostics International Sdn. Bhd., Selangor,
Malaysia). PanLF Rapid containsBmR1 andBmSXP test lines
and is meant for use in areas with mainly brugian ﬁlariasis, but
with possible co-occurrence of bancroftian ﬁlariasis, such as
inMalaysia.7,8 The concentration and purity ofBmSXPused in
PanLF Rapid is lower than that used in BLF Rapid. The higher
protein concentration in BLF Rapid increases its diagnostic
sensitivity, whereas the higher protein purity ensures a high
diagnostic speciﬁcity. The BLF Rapid test is performed by
pipetting 30 μL of serum sample into the square-bottom well
or 35μLofwhole blood is placed in the squarewell followedby
a drop of chase buffer. The sample is allowed to ﬂow by
capillary action until the sample reaches position A. Three
dropsof chasebuffer are added toa topovalwell to release the
anti-human IgG4-gold conjugate; followed by pulling a clear
plastic tab at the bottom of the cassette. One drop of chase
buffer is then added in the square-bottom well. This step re-
duces the ﬂow rate of the gold conjugated-IgG4 down the
membrane strip, thus allowing more interaction time between
the gold conjugated-IgG4 and anti-ﬁlarial IgG4 that bind with
BmSXP recombinant protein on the test line (position C).
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Results are recorded 15 minutes after the last step for serum
samples or after 25minutes for whole blood samples. The test
is read as positive when two red lines (test and control lines)
appear (Figure 1B). If only the control line is observed, the test
is read as negative (Figure 1C).
The diagnostic sensitivity of the prototype BLF Rapid was
assessed by testing with samples that had previously been
determined to be positive for bancroftian ﬁlariasis by other
tests. The other tests were mainly microscopic detection of
W. bancroftimicroﬁlaria (mf) in blood and/or antigen detection
tests in serum/plasma that is ICT, TropBio Og4C3 enzyme-
linked immunosorbent assay (ELISA) (Cellabs Pty. Ltd.,
Brookvale,NewSouthWales,Australia), and/orAD12-ELISA.9
To assess the diagnostic speciﬁcity of BLF Rapid, it was
testedwith serumsamples from individuals infectedwithother
parasitic infections from non-LF areas or healthy individuals
either from LF and non-LF areas. Those from LF areas were
negative by both ICT and Og4C3-ELISA.
BLF Rapid was ﬁrst evaluated at USM (in-house) using 96
serum samples, which included 55 samples fromW. bancrofti
mf-positive individuals from endemic areas in India and
Egypt. Serum samples from other infections (n = 31) at USM
were from patients with ascariasis, trichuriasis, hookworm
infection, strongyloidiasis, toxocariasis, hydatid disease,
amoebic liver abscess, and toxoplasmosis. Ten serumsamples
from healthy individuals were also tested. In addition, serial
2-fold dilutions of 27 of the abovementioned mf-positive sam-
pleswere testedwithBLFRapidandPanLFRapid (bothcontain
BmSXP recombinant antigen) to determine the difference in
sensitivity between the two tests.
BLFRapidwas then couriered to three international and two
national (Malaysian) laboratories and were independently
tested for its diagnostic sensitivity and speciﬁcity by their re-
spective laboratory personnel using their own stored serum
samples from previous studies. At the National Institutes of
Health-International Center for Excellence in Research, Na-
tional Institute of Research in Tuberculosis in India, 78 serum
samples were tested, which included 28 samples from
W. bancrofti–endemic area residents in India (different from
the samples from India usedatUSM)whowerepositive by two
antigen detection tests that is ICT and Og4C3 ELISA. In ad-
dition, 50 samples fromhealthy individuals from the samearea
were tested for diagnostic speciﬁcity, and these sampleswere
negative by ICT and Og4C3-ELISA. At the Centers for Dis-
easeControl and Prevention (CDC) in Atlanta, GA, 48 samples
were tested which included 10 healthy serum samples and 38
samples from W. bancrofti mf-positive individuals from en-
demic areas in Haiti who were previously positive by Bm14-
ELISA.10 In addition, some had previous positive ICT results.
At the Washington University School of Medicine in St. Louis,
MO, BLF Rapid was tested with 23 positive samples from
W. bancroftimf-positive individuals from endemic areas in Sri
Lanka, whichwere also positive, by AD12-ELISA. Ten positive
samples from Malaysia were from symptomatic patients (mi-
grant workers) suspected of LF. At the University of Malaya,
Malaysia, threeweremf and ICT positive and at the Insitute for
Medical Research, seven were ICT positive. At the University
of Malaya, two sera from other infections (toxoplasmosis and
amoebiasis) and one healthy serum were also tested. The di-
agnostic sensitivity and speciﬁcity of BLF Rapid was calcu-
lated for each laboratory. The average percentage of the
sensitivity and speciﬁcity across all laboratories, excluding
USM (i.e. data from independent evaluation), was then de-
termined. All laboratories used their stored serum samples in
accordance with the guidelines of their respective human re-
search ethics committees.
The results of the evaluations are shown in Table 1. TheBLF
Rapid was 100% sensitive and speciﬁc when tested at USM.
Testing of 2-fold serially diluted serum samples showed that
FIGURE 1. Diagrammatic representation of the BLF Rapid. (A) Un-
used test. (B) Positive result. (C) Negative result. This ﬁgure appears in
color at www.ajtmh.org.
TABLE 1
Diagnostic sensitivity and speciﬁcity evaluation results of BLF Rapid using stored serum samples at each laboratory
Institution
Reactivity with different types of sera
Sensitivity (%) Speciﬁcity (%)Wb Tests used to determine Wb infection Other infections Healthy
USM 55/55 mf 0/31* 0/10 100 100
UM 3/3 mf and ICT 0/2† 0/1 100 100
IMR 7/7 ICT – – 100 –
NIH-NIRT-ICER 28/28 ICT and Og4C3-ELISA – 0/50 100 100
CDC 32/38 mf and/or ICT and/or Bm14-ELISA – 0/10 84 100
WUSTL 23/23 mf and AD12-ELISA – – 100 –
Average‡ 93/99 (94%) – – – – 100
CDC=Centers for DiseaseControl and Prevention, Atlanta, GA; ICT = Filariasis card test; IMR= Institute forMedical Research,Malaysia;mf =microﬁlaria; NIH-NIRT-ICER=National Institutes of
Health-International Center for Excellence inResearch,National Institute of Research in Tuberculosis, India; UM=University ofMalaya,Malaysia; USM=Universiti SainsMalaysia;Wb=Wuchereria
bancrofti infection; WUSTL = Washington University School of Medicine, USA.
* Serum samples were from patients living in non-LF endemic areas with ascariasis, trichuriasis, hookworm infection, strongyloidiasis, toxocariasis, hydatid disease, amoebic liver abscess, and
toxoplasmosis.
† Serum samples were from patients living in non-LF endemic areas with toxoplasmosis and amoebiasis.
‡ Average sensitivity and speciﬁcity were calculated from percentage values across all laboratories excluding USM.
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BLF Rapid detected ﬁlarial-speciﬁc antibodies in 22 of 27
(81%) samples at 1–2 higher dilution than that detected by
PanLF Rapid. This showed that BLF Rapid was able to detect
lower antibody titres (thus more sensitive) as compared with
PanLF Rapid. The results of the independent evaluations
showed that the diagnostic sensitivity of BLF Rapid ranged
from84% to 100%,with amean of almost 94% (93/99) across
the laboratories. Except for the results at CDC, all laboratories
showed that BLF Rapid was 100% sensitive. Centers for
Disease Control and Prevention recorded 84% (32/38) di-
agnostic sensitivity for BLF Rapid, three of the six false neg-
ative sampleswere also negative byBm14-ELISA. The reason
for the lower sensitivity of BLF Rapid when tested at CDCwith
samples from Haiti is unknown; however, some of the false-
negative samples could be from people who were deﬁcient in
IgG4. It would be useful to test BLF Rapid with a much larger
number of serumsamples fromHaiti, preferably using recently
collected samples.
A diagnostic speciﬁcity of 100%was recorded at all centers
when tested with sera of subjects with non-lymphatic ﬁlarial
infections. At Washington University in St. Louis, MO, BLF
Rapid was also tested with patient sera from fourOnchocerca
volvulus and twoMansonella perstans infections, and all were
positive by the rapid test. Previous studies had reported
cross-reactivity of BmSXP protein with sera from people with
Loa loa and O. volvulus infections.4,5 Thus, the BLF Rapid
is not suitable to be used in areas co-endemic with non-
lymphatic ﬁlariae.
Anti-ﬁlarial antibodies are detectable before circulating ﬁ-
larial antigens or mf during the course of infection.11 Because
antibody response against ﬁlarial antigens is a sensitive
marker of LF exposure, it can be used as a tool to assess LF
transmission and to guide programmatic decisions.12,13 Thus,
as prevalence declines in a bancroftian ﬁlariasis area, a rapid
antibody test shouldbeusedalongside theFilariasis Test Strip
antigen test to obtain data on the status of the program. An
antibody test would be more sensitive in detecting exposure
or infection in young children in the post-MDA period.14,15
Another prototype rapid IgG4 test for detection of bancroftian
ﬁlariasis uses Wb123 recombinant protein. When compared
with an IgG4-ELISA based on the same antigen, both test
formats showed high diagnostic sensitivity and speciﬁcity.
Furthermore, the rapid test basedonWb123 antigen has good
speciﬁcity and does not detect antibodies in sera from per-
sons infected with the non-LF ﬁlaria L. loa and O. volvulus.16
A rapid antibody test would also be very useful for post-
elimination surveillance to monitor possible re-emergence of
active transmission and to conﬁrm sustained absence of LF
transmission. In addition, an antibody test would aid in the
detection of new infections caused by inﬂux of migrants from
anendemic region to either a non-endemic area or an area that
had succeeded in eliminating LF.16 In a recent seroprevalence
study among migrant workers in Malaysia, BLF Rapid was
positive in 19.6% workers from India (10/51), 12.6% from
Nepal (13/103), and 7.1% from Myanmar (1/14).7
In conclusion, thepresent studyshowed thatBLFRapid test
is a highly sensitive and speciﬁc test for detection of ban-
croftian ﬁlariasis in areas not endemic forO. volvulus or L. loa.
The encouraging evaluation results and the ﬁeld-applicability
make the test a potential diagnostic tool to complement an-
tigen results for TAS-stopping decisions and possibly for
post-elimination surveillance. Along with the Wb123-based
rapid test and other prototype rapid tests that may be in the
development pipeline, BLF Rapid should be further tested in
the ﬁeld and under operational conditions to determine the
best test that can be recommended by the World Health Or-
ganization for the aforementioned purposes.
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